VIDEO - Expert: Medical Path Helping Psychedelics Investment Story

Matt Carr from the Oxford Club chatted with INN about his excitement for the psychedelics investment market.

A new era of medicine may be on the rise thanks to growing interest in psychedelic drug development, according to one investment expert.

Matt Carr, chief trends strategist at the Oxford Club, spoke to the Investing News Network (INN) about why he’s bullish on the potential for psychedelic medicine.

“This is a great opportunity for investors to come in and get educated about the market,” Carr said, noting that there are still very few public companies out there.

Carr has spent a lot of time evaluating the investment opportunity in cannabis, which is another trendy drug market. He told INN that while the psychedelics and cannabis markets operate in very different ways, he has noticed some similarities between them.

“Right now, the psychedelic medicine market feels like the cannabis market a decade ago,” he said, describing the current crop of early stage psychedelics companies trying to get the ball rolling on the development of a new regulated drug industry.

Carr is encouraged by the medical benefits of psychedelic substances, and by the impact that refining these benefits could have. “That’s paving the way for a new era of medicine,” he said.

Carr told INN that in his view, Compass Pathways (NASDAQ:CMPS) is the clear frontrunner at the moment in terms of the public psychedelics companies available.

Watch the video above to hear Carr’s full thoughts on the outlook for psychedelics investments. You can also click here for more video interviews on our YouTube page.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Featured
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows: Evercore ISI 4 th Annual HEALTHCONx Virtual Conference: fireside chat at 9:40am ET on 1 December 2021. The fireside chat will feature Augustus John Rush MD, Adjunct Professor in the ...

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows:

  • Evercore ISI 4 th Annual HEALTHCONx Virtual Conference: fireside chat at 9:40am ET on 1 December 2021. The fireside chat will feature Augustus John Rush MD, Adjunct Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine

  • H.C. Wainwright 2nd Annual Psychedelics Conference: panel "Three Forms of Psilocybin" at 10:00am ET on 6 December 2021 and presentation available on demand

  • Berenberg European Conference 2021: virtual one-on-one meetings on 8 December 2021

A live audio webcast of the Evercore fireside chat and the H.C. Wainwright presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following each event. For more information, please visit ir.compasspathways.com.

read more Show less
Revenue of $14.5 million increased 53% from prior year period Gross profit income of $3.5 million increased 151% from prior year period Net income was $0.4 million versus a loss of $0.6 million in prior year period Adjusted EBITDA was $1.2 million, versus a loss of $0.6 million in prior year period Maintained a strong liquidity position, including a cash & cash equivalents balance of $7.6 million an increase of ...

Revenue of $14.5 million increased 53% from prior year period

Gross profit income of $3.5 million increased 151% from prior year period

read more Show less
IX Biopharma will receive an initial US$9 million upfront payment Eligible for up to US$239 million in development and sales milestone payments Double digit royalties on future product sales of any licensed product IX Biopharma Ltd a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its ...
  • iX Biopharma will receive an initial US$9 million upfront payment
  • Eligible for up to US$239 million in development and sales milestone payments
  • Double digit royalties on future product sales of any licensed product

IX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

read more Show less

MARKETS

Markets
TSX20785.60-363.40
TSXV939.06-15.20
DOW34527.28-608.66
S&P 5004573.67-81.60
NASD15539.32-243.51
ASX7239.80-39.50

COMMODITIES

Commodities
Gold1772.44-14.19
Silver22.81-0.11
Copper4.31-0.03
Palladium1739.00-49.92
Platinum940.73-25.27
Oil66.94-3.01
Heating Oil2.09-0.06
Natural Gas4.61-0.24